AHH will make an investment of Rs. 600 crore in the company through a mix of primary and secondary infusion
The market capitalization of the company stood at Rs. 7,000 crore +
Patient Advisory Councils (PACs) to be set up across hospitals to make patients true partners in enhancing patient safety and improving care delivery
Public private partnership (PPP) with integrated strategy essential to achieve ‘TB Mukt Bharat’ by 2025
Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi (Sovateltide)
The new logo incorporates three beating hearts seamlessly & reinforces 'healthcare with a heart' into the Group's visual identity
The product is expected to start contributing meaningfully to the revenue from FY25
The inspection classification was determined by the agency as Voluntary Action Indicated
Sets price band at ?695 to ?735 per Equity Share
Subscribe To Our Newsletter & Stay Updated
